Sumit Sheoran | Cancer Biomarkers | Innovative Research Award

Published on by Oncology

Innovative Research Award

Sumit Sheoran
Babasaheb Bhimrao Ambedkar University

                          Sumit Sheoran
Affiliation Babasaheb Bhimrao Ambedkar University
Country India
Scopus ID 57755350400
Documents 10
Citations 188
h-index 5
Subject Area Cancer Biomarkers
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0002-2519-8506

The Innovative Research Award recognizes emerging and impactful scientific contributions in oncology-related research. Sumit Sheoran has established a scholarly profile in cancer biomarker investigations, with publications indexed in major academic databases and measurable citation impact. His research activities demonstrate engagement with molecular oncology, biomarker discovery, and translational biomedical science, contributing to the broader understanding of cancer diagnosis and therapeutic development.[1][2]

Abstract

Sumit Sheoran is a researcher associated with Babasaheb Bhimrao Ambedkar University whose academic activities focus on cancer biomarkers and related biomedical investigations. His scholarly record includes peer-reviewed publications indexed in Scopus, demonstrating contributions to oncology-oriented research and translational scientific studies. With documented citation performance and a growing research profile, his work supports ongoing efforts to improve understanding of disease mechanisms, biomarker identification, and evidence-based clinical applications. The combination of publication output, citation recognition, and engagement in cancer research highlights a profile aligned with contemporary priorities in oncology and biomedical innovation.[1][2]

Keywords

  • Cancer Biomarkers
  • Oncology Research
  • Translational Medicine
  • Molecular Diagnostics
  • Biomedical Research
  • Cancer Biology

Introduction

Cancer biomarker research plays a central role in advancing precision medicine, early diagnosis, prognostic assessment, and therapeutic monitoring. Sumit Sheoran’s academic work is positioned within this evolving field, emphasizing scientific inquiry that contributes to the understanding of cancer-related biological processes. Through peer-reviewed publications and scholarly engagement, his research supports evidence generation relevant to contemporary oncology challenges and emerging diagnostic strategies.[1]

Research Profile

Affiliated with Babasaheb Bhimrao Ambedkar University, Sumit Sheoran maintains a documented scholarly presence through Scopus, ORCID, Google Scholar, and ResearchGate profiles. His publication record includes ten indexed documents with citation activity reflecting academic visibility. The research profile demonstrates continued participation in oncology-related investigations and interdisciplinary biomedical research initiatives.[1][2]

Research Contributions

The research contributions of Sumit Sheoran are associated with cancer biomarker discovery, molecular characterization, and biomedical investigations relevant to oncology. His scholarly outputs contribute to scientific discussions concerning disease detection, biomarker validation, and translational research applications. These efforts support broader objectives aimed at improving diagnostic accuracy and strengthening evidence-based cancer research frameworks.[1]

Publications

The researcher has produced ten Scopus-indexed publications addressing themes related to cancer biomarkers and biomedical sciences. These publications have accumulated citation recognition within the scholarly community and contribute to the dissemination of scientific knowledge. Publication activity demonstrates sustained participation in peer-reviewed research and academic communication within relevant scientific disciplines.[1]

Research Impact

Research impact is reflected through documented citation metrics, publication visibility, and engagement within oncology research networks. With 188 citations and an h-index of 5, the available bibliometric indicators suggest that the research outputs have contributed to ongoing scientific discourse. Such indicators provide evidence of academic relevance and scholarly recognition.[3]

Award Suitability

The Innovative Research Award emphasizes scientific originality, measurable research outcomes, and disciplinary relevance. Sumit Sheoran’s documented publication record, citation performance, and specialization in cancer biomarkers align with these evaluation dimensions. His contributions to oncology-focused research provide a reasonable basis for consideration within an international research recognition framework.[1][4]

Conclusion

Sumit Sheoran has developed an emerging research profile characterized by contributions to cancer biomarker studies, peer-reviewed publications, and measurable citation impact. His scholarly activities support the advancement of oncology research and demonstrate alignment with the objectives of international scientific recognition programs that value innovation, research quality, and academic engagement.[1][2]

References

  1. Elsevier. (n.d.). Scopus author details: Sumit Sheoran, Author ID 57755350400. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57755350400
  2. ORCID. (n.d.). Sumit Sheoran: ORCID record 0000-0002-2519-8506.
    https://orcid.org/0000-0002-2519-8506
  3. Google Scholar. (n.d.). Scholar profile of Sumit Sheoran.
    https://scholar.google.com/citations?hl=en&user=sz3r5rQAAAAJ
  4. ResearchGate. (n.d.). Sumit Sheoran research profile and scholarly outputs.
    https://www.researchgate.net/profile/Sumit-Sheoran-8

Nour Abu Jayab | Cancer Cell Biology | Innovative Research Award

Published on by Oncology

Innovative Research Award

Nour Abu Jayab
University of Sharjah

                 Nour Abu Jayab
Affiliation University of Sharjah
Country United Arab Emirates
Scopus ID 58147288600
Documents 5
Citations 110
h-index 4
Subject Area Cancer Cell Biology
Event International Research Awards on Oncology and Cancer Research

Nour Abu Jayab is a researcher affiliated with the University of Sharjah whose scholarly activities contribute to the advancement of cancer cell biology and related biomedical investigations. Her publication record, citation performance, and research visibility demonstrate active engagement in contemporary oncology research. The Innovative Research Award recognizes scientific contributions that support the understanding of cancer mechanisms, translational biology, and evidence-based innovation within oncology and cancer research disciplines.[1][2]

Abstract

Nour Abu Jayab has established a developing research profile within cancer cell biology through contributions focused on understanding cellular mechanisms associated with cancer progression and therapeutic response. Her scholarly output demonstrates engagement with contemporary oncology challenges, including translational research and biomedical innovation. With a documented publication record and measurable citation impact, her work has contributed to scientific discussions within oncology-related disciplines. The combination of research productivity, interdisciplinary collaboration, and influence reflected through citation metrics supports recognition for innovative scientific achievement within the framework of the International Research Awards on Oncology and Cancer Research.[1][2]

Keywords

Cancer Cell Biology, Oncology Research, Translational Medicine, Cancer Mechanisms, Biomedical Research, Cellular Signaling, Tumor Biology, Scientific Innovation, Cancer Therapeutics, Research Impact

Introduction

Cancer research continues to rely on innovative investigations that improve understanding of cellular behavior, disease progression, and treatment response. Nour Abu Jayab contributes to this field through scholarly activities focused on cancer cell biology, supporting scientific knowledge relevant to modern oncology and translational biomedical research.[1]

Research Profile

Affiliated with the University of Sharjah, Nour Abu Jayab has developed a research portfolio within oncology-related disciplines. Her Scopus-indexed publications, citation performance, and measurable h-index indicate growing academic visibility and engagement with topics connected to cancer biology and biomedical sciences.[1][2]

Research Contributions

Her research contributions support understanding of biological processes relevant to cancer development and treatment. Through peer-reviewed publications, she has participated in advancing scientific evidence, encouraging interdisciplinary collaboration, and contributing to the broader knowledge base that informs future oncology investigations.[1][3]

Publications

The researcher maintains a Scopus-indexed publication record consisting of five documented scholarly works. These publications collectively address themes associated with cancer biology and biomedical research, contributing to scientific communication and supporting evidence-based advancement within oncology-related fields.[1]

Research Impact

With more than one hundred citations and an established h-index, Nour Abu Jayab’s research demonstrates measurable scholarly influence. Citation activity indicates that her publications have been referenced by other researchers, reflecting relevance and contribution to ongoing discussions within cancer and biomedical sciences.[1][2]

Award Suitability

The Innovative Research Award recognizes originality, scientific contribution, and research influence. Based on documented publication metrics, citation performance, and engagement in cancer cell biology, Nour Abu Jayab demonstrates characteristics aligned with award criteria emphasizing innovation, academic excellence, and contributions to oncology research.[1]

Conclusion

Nour Abu Jayab’s scholarly profile reflects active participation in cancer cell biology research. Her publication record, citation impact, and contribution to oncology-related knowledge support recognition within international research award programs that value innovation, scientific rigor, and meaningful advancement of biomedical science.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Nour Abu Jayab, Author ID 58147288600. Scopus.https://www.scopus.com/authid/detail.uri?authorId=58147288600
  2. Abu Jayab, N., Abed, A., Talaat, I. M., & Hamoudi, R. (Year). The molecular mechanism of NF-κB dysregulation across different subtypes of renal cell carcinoma.https://pmc.ncbi.nlm.nih.gov/articles/PMC12147641/
  3. ResearchGate. (n.d.). Nour Abu Jayab Research Profile and Publications.https://www.researchgate.net/profile/Nour-Abu-Jayab

Dr. Osnat Elyashiv | Oncology Therapy | Research Excellence Award

Published on by Oncology

Dr. Osnat Elyashiv | Oncology Therapy | Research Excellence Award 

Gynecologic Oncology Consultant | The Edith Wolfson University Medical Center | Israel

Dr. Osnat Oxana Elyashiv’s research centers on gynecologic oncology, with a strong focus on ovarian and endometrial cancers, integrating clinical trials, surgical outcomes, and translational science. Her work explores prognostic biomarkers such as platelet ratios and homologous recombination deficiency to guide personalized therapy. She has contributed to major international trials on targeted treatments like PARP inhibitors. Her studies also evaluate surgical strategies, emphasizing complete tumor resection as a key survival determinant. Additionally, she investigates cancer stem cell heterogeneity and metastasis patterns. Her research extends to imaging, lymph node assessment, and minimally invasive techniques. Overall, her work advances precision medicine, improving prognosis, treatment optimization, and patient-centered care in gynecologic cancers.

Citation Metrics (Google Scholar)

298
200
100
50
0

Citations

298

h-index

9

i10-index

9

Citations

h-index

i10-index

View Google Scholar Profile

Featured Publications

 

Ayda Ahmadi | Pancreatic Cancer | Best Researcher Award

Published on by Oncology

Ms. Ayda Ahmadi | Pancreatic Cancer | Best Researcher Award 

Student | Sahand University of Technology | Iran

Ms. Ayda Ahmadi is an emerging young researcher in biomedical and pharmaceutical engineering whose academic performance, early research productivity, and strong technical training collectively position her as a promising candidate for a Best Researcher Award. Currently pursuing her M.Sc. in Chemical Engineering with a specialization in Pharmaceutical Engineering at Sahand University of Technology, she holds a solid academic foundation built on a high-performing B.Sc. in Biomedical Engineering (Biomaterials) from Khayyam University. Her hands-on experience includes two extensive 240-hour internships at Samen Pharmaceutical Company—where she gained valuable skills in pharmaceutical formulation, sterile production systems, GMP-based quality control, and laboratory documentation—and in a Dental Prosthesis Laboratory, where she developed practical expertise in biomaterials fabrication relevant to tissue engineering and biomedical device applications. Ayda’s research output reflects her focus on advanced drug delivery systems, nanotechnology, and biomaterials, demonstrated through significant works such as the preparation and characterization of silica nanoparticles and aerogels for smart drug delivery, the design of targeted nanocarriers for anticancer drug delivery to pancreatic tumors, and the study of calcium sulfate for treating bone infections in diabetic patients. With manuscripts submitted and under review, she shows early publication initiative and a clear commitment to building a strong scientific portfolio. Her technical proficiency across COMSOL Multiphysics, MATLAB, Aspen HYSYS, OriginPro, and data management tools further enhances her research capability, supported by multiple certifications. Ayda’s research interests—spanning nanostructure functionalization, controlled antibiotic release, and biomedical applications of engineered materials—align strongly with global research priorities in precision medicine and therapeutic innovation. Motivated to participate in international conferences and collaborative projects, she demonstrates ambition, discipline, and scientific curiosity, making her a suitable and competitive candidate for recognition in young researcher or early-career researcher award categories.

Profile: ORCID

Featured Publications

  1. Ahmadi, A., Souri, A., & Moghaddas, J. S. (2025). Preparation, characterization, and application of silica nanoparticles and silica aerogel in smart drug delivery systems. Manuscript submitted for publication.

  2. Ahmadi, A., Souri, A., & Moghaddas, J. S. (2025). Design and development of smart nanocarriers for targeted delivery of anticancer drugs to pancreatic tumors: A review study. Manuscript under review.

  3. Ahmadi, A. (2024). Investigation of the effect of calcium sulfate in the treatment of bone infections in diabetic patients. Unpublished research project, Khayyam University.

  4. Ahmadi, A. (2024). Surface modification of silica aerogel for drug delivery in the treatment of bone infection in diabetic patients. Unpublished research study, Sahand University of Technology.

  5. Ahmadi, A., Souri, A., & Moghaddas, J. S. (2024). Development of functionalized nanostructures for controlled antibiotic release in infectious diseases. Unpublished manuscript.

Ms, Ayda Ahmadi’s research advances next-generation drug delivery systems and biomaterial-based therapeutics, contributing to safer, more effective treatments for cancer and infectious diseases. Her innovative work in nanotechnology and smart drug carriers supports global medical innovation by improving targeted therapy, reducing side effects, and addressing critical healthcare challenges.

Jaweher Bday | Cancer Research | Best Researcher Award

Published on by Oncology

Ms. Jaweher Bday | Cancer Research | Best Researcher Award 

PhD Student | Higher Institute of Biotechnology of Monastir | Tunisia

Ms. Jaweher Bday is a highly promising PhD researcher in biotechnology with a robust specialization in immuno-oncology, demonstrating strong potential and clear suitability for a Best Researcher Award through her scientific rigor, technical depth, and impactful research outputs. Her academic journey—from a bachelor’s degree in molecular and cellular biology, a research master’s in cell biology and physiology, to an ongoing PhD at the Higher Institute of Biotechnology of Monastir—illustrates continuous progression and dedication to cancer research. She has completed several competitive international research internships in leading laboratories in France, including the Bio PeroxIL Laboratory at the University of Burgundy and the INSERM U1307 Laboratory at the University of Nantes, enhancing her expertise in cell death mechanisms, tumor biology, and advanced molecular techniques. Her publication record is strong and growing, with peer-reviewed articles in recognized journals on topics such as arginase regulation in HPV infection, hybrid cell-death induction in breast cancer models, and the role of nitric oxide pathways in cervical carcinogenesis, along with an additional submitted manuscript on HPV circulating markers. Jaweher’s scientific maturity is evidenced by her active participation in conferences, including oral and poster presentations at national and international oncology and toxicology meetings, reflecting substantial dissemination of her research. Beyond laboratory excellence, she demonstrates leadership through major roles in the Tunisian Association of Biotechnology Students, including serving as President and spearheading scientific events and innovation-focused programs. Her teaching activities, spanning workshops, directed courses, and hands-on training, further showcase her commitment to academic development and knowledge transfer. Equipped with advanced laboratory skills, strong analytical proficiency using tools like FlowJo, ImageJ, SPSS, and GraphPad, along with extensive training in scientific writing, publishing, quality management, and pedagogy, she embodies the qualities of an emerging researcher with both scientific impact and community engagement. Overall, her achievements, productivity, international exposure, and leadership make her an excellent candidate for a Best Researcher Award.

Profile: ORCID

Featured Publications

  1. Souid, M., Bday, J., Souissi, S., Ghedira, R., Gabbouj, S., Shini-Hadhri, S., Toumi, D., Bergaoui, H., Zouari, I., Faleh, R., Zakhama, A., & Hassen, E. (2023). Arginase is upregulated in healthy women infected by oncogenic HPV types. Biomarkers, 28(7), 628–636.

  2. Bday, J., Souid, M., Pires, V., Gabbouj, S., Véjux, A., Lizard, G., & Hassen, E. (2025). Arginase activity inhibition with thymoquinone induces a hybrid type of cell death in MDA-MB-231 cell line. Journal of Biochemical and Molecular Toxicology, 39(2), e70130.

  3. Bday, J., Souid, M., Farhat, K. H., Macherki, Y., Ghedira, R., Gabbouj, S., Shini-Hadhri, S., Faleh, R., & Hassen, E. (2025). Involvement of endothelial nitric oxide synthase (eNOS) and nitric oxide (NO) levels in precancerous and cancerous cervical lesions. Nitric Oxide, 159, 176–185.

  4. Souid, M., Ghedira, R., Bday, J., Gabbouj, S., Shini-Hadhri, S., Hajji, A., Faleh, R., & Hassen, E. (Under review). Human Papillomavirus-16 circulating markers distribution among unvaccinated women. Infectious Diseases Now.

  5. Bday, J., Souid, M., Pires, V., Véjux, A., Lizard, G., & Hassen, E. (2025). Hybrid cell-death mechanisms in breast cancer: Insights from thymoquinone-mediated arginase inhibition. Manuscript in preparation.

Ms. Jaweher Bday’s work advances immuno-oncology by uncovering novel cellular and molecular mechanisms that can drive more precise cancer diagnostics and targeted therapies. Her research contributes to global health by improving understanding of HPV-related cancers and breast cancer biology, supporting innovations that can shape future clinical and translational applications. Through scientific leadership, teaching, and community engagement, she helps strengthen research capacity and fosters the next generation of biotechnology innovators.

Okechukwu Obulezi | Blood Cancer | Best Paper Award

Published on by Oncology

Dr. Okechukwu Obulezi | Blood Cancer | Best Paper Award 

Lecturer | Nnamdi Azikiwe Univeristy | Nigeria

Dr. Okechukwu Jeremiah Obulezi, Ph.D., is a distinguished statistician whose academic trajectory, research productivity, and multidisciplinary impact make him exceptionally suitable for a Best Paper Award. With a strong foundation in Statistics from Nnamdi Azikiwe University and Abia State Polytechnic, culminating in a Ph.D. focused on developing innovative generalized distribution families through Logistic-X transformations, he has consistently advanced statistical theory and its applications. His research interests span probability distributions, machine learning models, survival analysis, competing risks, acceptance sampling, optimum sampling, mask data and censoring schemes—areas crucial to modern data-driven decision-making in engineering, biomedical sciences, public health, and socio-economic modelling. Dr. Obulezi’s publication record is extensive and impactful, with over forty peer-reviewed journal articles in reputable outlets such as Heliyon, Scientific African, Alexandria Engineering Journal, Entropy, Symmetry, AIP Advances, and Earthline Journal of Mathematical Sciences. His works introduce new probability distributions, propose enhanced estimation techniques, develop sampling plans, and apply machine learning to real-world problems such as financial volatility, disease survival modelling, COVID-19 mortality, rainfall analysis, transportation cost prediction, and biomedical datasets. His methodological sophistication and ability to translate theory into practical applications underscore his scholarly depth. Professionally, he serves as Lecturer I at Nnamdi Azikiwe University and holds several academic leadership roles, including Seminar & Project Coordinator and member of multiple university committees. His international academic influence is further demonstrated through active service as a reviewer for renowned journals under Springer, Elsevier, Taylor & Francis, and Scopus-indexed platforms. Dr. Obulezi’s conference contributions and book chapter reviews further affirm his commitment to advancing statistical knowledge. Collectively, his robust research output, innovative contributions to distribution theory, interdisciplinary relevance, and sustained scholarly engagement establish him as a highly deserving candidate for the Best Paper Award.

Profile: Google Scholar 

Featured Publications

  1. Onyekwere, C. K., & Obulezi, O. J. (2022). Chris-Jerry distribution and its applications. Asian Journal of Probability and Statistics, 20(1), 16–30.

  2. Chinedu, E. C. Q., Chukwudum, Q. C., Alsadat, N., Obulezi, O. J., Almetwally, E. M., & Others. (2023). New lifetime distribution with applications to single acceptance sampling plan and scenarios of increasing hazard rates. Symmetry, 15(10), 1–33.

  3. Orji, G. O., Etaga, H. O., Almetwally, E. M., Igbokwe, C. P., Aguwa, O. C., & Obulezi, O. J. (2025). A new odd reparameterized exponential transformed-X family of distributions with applications to public health data. Innovation in Statistics and Probability, 1(1), 88–118.

  4. Obulezi, O. J., Anabike, I. C., Oyo, O. G., Harrison, E., & Perpetua, I. C. (2023). Marshall-Olkin Chris-Jerry distribution and its applications. International Journal of Innovative Science and Research Technology, 8(5), 1–15.

  5. Anabike, I. C., Igbokwe, C. P., Onyekwere, C. K., & Obulezi, O. J. (2023). Inference on the parameters of Zubair-Exponential distribution with application to survival times of guinea pigs. Journal of Advances in Mathematics and Computer Science, 38(7), 12–35.

By creating forward-looking statistical frameworks with real-world applications, the nominee’s research bridges science and society, enabling smarter policies, stronger industries, and transformative technological progress.

Sanaz Alaeejahromi | Reproductive Cancer | Best Researcher Award

Published on by Oncology

Dr. Sanaz Alaeejahromi | Reproductive Cancer | Best Researcher Award

Assistant Professor | Shiraz University of Medical Sciences | Iran 

Dr. Sanaz Alaee is an accomplished reproductive biologist and clinical embryologist whose extensive academic, clinical, and research contributions make her an exceptional candidate for a Best Researcher Award. With over a decade of experience, she has built a distinguished career spanning reproductive toxicology, infertility treatment, ART technologies, and stem cell–based therapeutics. Her academic foundation includes a top-ranked PhD in Reproductive Biology, followed by faculty service at Shiraz University of Medical Sciences, where she has led the Reproductive Biology Department, directed the Reproductive Biology Lab, and currently serves as Director of the IVF Laboratory at Hazrat Zeinab Educational Medical Center. Her research portfolio is substantial, with more than 30 peer-reviewed publications covering critical topics such as implantation failure, ovarian and testicular toxicology, stem cell secretome therapy, PCOS biomarkers, assisted reproductive technologies, and oocyte/follicle maturation. A major highlight of her recent work includes a nationally funded project exploring extracellular vesicles from Wharton’s jelly mesenchymal stem cells for restoring fertility after chemotherapy—a promising direction for male infertility, especially among cancer survivors. She is internationally engaged, collaborating with researchers from the USA, UK, Australia, India, South Korea, Taiwan, UAE, and Kazakhstan, and remains active in global societies such as ESHRE, through which she is a certified Clinical Embryologist. Her editorial and peer-review influence is exemplary, with over 400 peer-reviews for high-impact journals, including Reproductive Sciences, Reproductive Toxicology, Scientific Reports, and PLOS ONE, demonstrating her commitment to scientific rigor and research integrity. Dr. Alaee has also contributed extensively to graduate education, curriculum development, and the supervision of MSc and PhD candidates. Her combined achievements in research innovation, clinical excellence, international collaboration, leadership, and scholarly service reflect a sustained and impactful contribution to reproductive biology, strongly supporting her suitability for a Best Researcher Award.

Profiles: Google Scholar | Scopus | ORCID | ResearchGate 

Featured Publications

  1. Monsefi, M., Alaee, S., Moradshahi, A., & Rohani, L. (2010). Cadmium‐induced infertility in male mice. Environmental Toxicology: An International Journal, 25(1), 94–102.

  2. Fazeli, M., Hassanzadeh, P., & Alaei, S. (2011). Cadmium chloride exhibits a profound toxic effect on bacterial microflora of the mice gastrointestinal tract. Human & Experimental Toxicology, 30(2), 152–159.

  3. Neisy, A., Zal, F., Seghatoleslam, A., & Alaee, S. (2019). Amelioration by quercetin of insulin resistance and uterine GLUT4 and ERα gene expression in rats with polycystic ovary syndrome (PCOS). Reproduction, Fertility and Development, 31(2), 315–323.

  4. Alaee, S. (2017). Role of essential oil of Mentha spicata (spearmint) in addressing reverse hormonal and folliculogenesis disturbances in a polycystic ovarian syndrome in a rat model. Advanced Pharmaceutical Bulletin, 7(4), 651–654.

  5. Kargar-Abarghouei, E., Vojdani, Z., Hassanpour, A., Alaee, S., & others. (2018). Characterization, recellularization, and transplantation of rat decellularized testis scaffold with bone marrow-derived mesenchymal stem cells. Stem Cell Research & Therapy, 9(1), 324.

Dr. Alaee’s work advances reproductive science by integrating stem-cell therapies, toxicology insights, and cutting-edge ART technologies to improve fertility outcomes. Her research directly contributes to societal well-being by offering new hope for cancer survivors and infertile couples.

Jun Lu | Cancer | Editorial Board Member

Published on by Oncology

Prof. Jun Lu | Cancer | Editorial Board Member

Professor | Chengdu University of Traditional Chinese Medicine | China

Dr. Jun Lu is a distinguished researcher at Chengdu University of Traditional Chinese Medicine, China, specializing in cancer nanomedicine, biomaterials, and translational therapeutics. His work focuses on the design and development of multifunctional nanoplatforms, including engineered chitosan nanoparticles, aptamer-conjugated chemotherapeutics, and self-gelling biomaterials for applications in tumor therapy, wound healing, and infectious disease management. Dr. Lu integrates molecular biology, materials science, and bioengineering to advance innovative therapeutic strategies, such as modulating tumor microenvironments, orchestrating DNA damage pathways in colorectal carcinoma, and promoting MRSA-infected wound healing. He has authored 78 publications in high-impact journals including Journal of Translational Medicine, Chemical Engineering Journal, Carbohydrate Polymers, and Nano Research, reflecting strong expertise in nanobiotechnology and translational oncology. His extensive collaborations with over 380 co-authors worldwide demonstrate his leadership in multidisciplinary research networks, bridging fundamental science with clinical applications. Beyond academic contributions, Dr. Lu’s work has significant societal impact by enabling advanced therapies for cancer, infectious diseases, and tissue repair, providing novel solutions to global health challenges. His research emphasizes translational relevance and real-world applicability, contributing to safer, more effective, and innovative therapeutic modalities. Dr. Lu’s academic influence and research productivity are reflected in his metrics 2,421 citations, 78 documents, and an h-index of 24.

Profiles: Google Scholar | Scopus | ORCID 

Featured Publications

Lu, J., Zhang, H., Hou, J., Li, X., Hu, X., Hu, Y., Easton, C. D., Li, Q., Sun, C., … (2020). Efficient metal ion sieving in rectifying subnanochannels enabled by metal–organic frameworks. Nature Materials, 19(7), 767–774. Cited by: 495

Ni, S., Yao, H., Wang, L., Lu, J., Jiang, F., Lu, A., Zhang, G. (2017). Chemical modifications of nucleic acid aptamers for therapeutic purposes. International Journal of Molecular Sciences, 18(8), 1683. Cited by: 384

Lu, J., Jiang, F., Lu, A., Zhang, G. (2016). Linkers having a crucial role in antibody–drug conjugates. International Journal of Molecular Sciences, 17(4), 561. Cited by: 352

Tan, C. M., Therien, A. G., Lu, J., Lee, S. H., Caron, A., Gill, C. J., Lebeau-Jacob, C., … (2012). Restoring Methicillin-Resistant Staphylococcus aureus susceptibility to β-lactam antibiotics. Science Translational Medicine, 4(126), 126ra35.
Cited by: 328

Li, F., Lu, J., Liu, J., Liang, C., Wang, M., Wang, L., Li, D., Yao, H., Zhang, Q., Wen, J., … (2017). A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer. Nature Communications, 8(1), 1390.
Cited by: 275

 

Sheeba Irshad | Tumour Immunology | Editorial Board Member

Published on by Oncology

Dr. Sheeba Irshad | Tumour Immunology | Editorial Board Member

Senior Clinical Lecturer | King’s College London | United Kingdom

Dr. Sheeba Irshad is a distinguished clinician-scientist at Guy’s Hospital, London, specializing in translational oncology, tumor immunology, and precision medicine, with a strong focus on breast cancer, immune surveillance, therapeutic resistance, oncolytic viro-immunotherapy, and treatment-related toxicities. Her pioneering work advances immune-based therapeutic innovation through Fc-engineered antibodies, viral vaccine–driven T-cell activation, immunomodulatory gene therapies, and strategies aimed at reversing T-cell exhaustion in poorly immunogenic tumors. She has authored 61 publications in leading journals such as Cancer Research, Molecular Therapy, Translational Oncology, and PLOS ONE, addressing critical challenges including breast cancer cardiotoxicity, radiation-induced fibrosis, and the complex interplay between viral immunity and tumor control. Dr. Irshad’s extensive global collaborations—spanning more than 1,300 co-authors—demonstrate her leadership within multidisciplinary cancer research networks and her commitment to integrating molecular biology, immunology, and clinical oncology to accelerate therapeutic translation. Her contributions have significantly influenced the development of safer and more effective immunotherapies, improving patient outcomes and shaping modern oncology practice worldwide. Dr. Irshad’s academic influence and research productivity are reflected in her metrics 2,293 citations, 61 documents, and an h-index of 22.

Profiles: Scopus| ORCID | LinkedIn

Featured Publications

Cheung, A., Chenoweth, A. M., Johansson, A., Laddach, R., Guppy, N., Trendell, J., Esapa, B., Mavousian, A., Navarro-Llinas, B., Haider, S., et al. (2024). Anti-EGFR antibody-drug conjugate carrying an inhibitor targeting CDK restricts triple-negative breast cancer growth. Clinical Cancer Research.

Hsu, R., Al-Zubeidy, B., Flores, D., Nazarian, A., Baugh, A., Gonzalez, E., Castanon, S., Xiu, J., Kang, I., Spicer, D., et al. (2024). Evaluation of markers of immunity in different metastatic immune microenvironments suggests more suppression within breast-to-liver metastases in breast cancer. Breast Cancer Research and Treatment.

Jahangir, C. A., Page, D. B., Broeckx, G., Gonzalez, C. A., Burke, C., Murphy, C., Reis-Filho, J. S., Ly, A., Harms, P. W., Gupta, R. R., et al. (2024). Image-based multiplex immune profiling of cancer tissues: Translational implications. Report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. The Journal of Pathology.

Tang, C. C., Timbres, J., Ramsey, K., Mera, A., Irshad, S., Sawyer, E., & Khan, A. (2023). Clinico-pathological co-variates define a predictive model of breast cancer-related lymphoedema (BCRL) in patients undergoing axillary surgery for breast cancer. Cancer Research.

Fatayer, H., O’Connell, R. L., Bannon, F., Coles, C. E., Copson, E., Cutress, R. I., Dave, R. V., Gardiner, M. D., Grayson, M., Holcombe, C., et al. (2023). Current practice and surgical outcomes of neoadjuvant chemotherapy for early breast cancer: UK NeST study (Vol. 109, p. 800, 2022). BJS.

Kimihide Kusafuka | Neck Cancer | Editorial Board Member

Published on by Oncology

Dr. Kimihide Kusafuka | Neck Cancer | Editorial Board Member

Clinical Physician | Shizuoka General Hospital | Japan

Dr. Kimihide Kusafuka is a distinguished pathologist at Shizuoka General Hospital, Japan, internationally recognized for his expertise in head and neck pathology, salivary gland tumors, and molecular oncopathology. His research has been instrumental in redefining diagnostic criteria, histopathological classifications, and gene alteration profiles across a spectrum of rare and aggressive neoplasms. Dr. Kusafuka has contributed significantly to the understanding of salivary duct carcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, and solitary fibrous tumors through large-cohort analyses, multi-institutional collaborations, and advanced molecular techniques, including MYB/MYBL1 rearrangement characterization, CRTC1/3-MAML2 fusion analysis, and the identification of novel tumor variants. His scholarly output comprises 100 peer-reviewed documents, reflecting a sustained commitment to translational pathology and precision diagnostics. With more than 380 collaborators worldwide, his work has shaped global guidelines, influenced tumor classification systems, and improved prognostic assessment models for clinicians and researchers in the field. Dr. Kusafuka’s studies spanning molecular pathology, surgical pathology, and carcinoma outcome prediction—continue to strengthen diagnostic accuracy and therapeutic decision-making, ultimately improving patient outcomes and contributing to the advancement of cancer pathology. His rigorous methodologies, cross-disciplinary partnerships, and leadership in multi-center Japanese cohorts highlight his role as a leading figure in contemporary oncologic pathology. Dr. Kusafuka’s academic influence and research productivity are reflected in his metrics: 1,768 citations, 100 documents, and an h-index of 25.

Profiles: Scopus| ORCID | ResearchGate

Featured Publications

Kusafuka, K., et al. (2022). A symptomatic intercalated duct lesion of the parotid gland: A case report with immunohistochemical and genetic analyses. Medical Molecular Morphology. Citations: 2

Kusafuka, K., et al. (2022). Salivary gland polymorphous adenocarcinoma: Clinicopathological features and gene alterations in 36 Japanese patients. Journal of Oral Pathology and Medicine.Citations: 6

Kusafuka, K., et al. (2022). Intraoral basal cell carcinoma of the soft palate: A diagnostic pitfall. Citations: 2

Kusafuka, K., et al. (2022). The implicated clinical factors for outcomes in 304 patients with salivary duct carcinoma: Multi-institutional retrospective analysis in Japan. Head & Neck.  Citations: 12

Kusafuka, K., et al. (2022). Salivary mucoepidermoid carcinoma: Histological variants, grading systems, CRTC1/3-MAML2 fusions, and clinicopathological features. Histopathology. Citations: 28